BioCardia regains Nasdaq stockholders equity compliance with ATM offering proceeds
BioCardia received notice on April 10, 2026 that its stockholders equity had fallen below the $2.5 million minimum required by Nasdaq Listing Rule 5550(b)(1). The company sold 4,004,330 shares of common stock from April 1 to June 5, 2026 at an average price of $1.27 under its At The Market offering agreement with H.C. Wainwright & Co., generating net proceeds of $4.9 million. Based on these transactions, the company believes it has regained compliance with the stockholders equity requirement as of the filing date, and Nasdaq has granted an extension to October 7, 2026 to sustain compliance.
Key facts
- Stockholders equity had fallen below $2,500,000 required minimum per Nasdaq Listing Rule 5550(b)(1)
- Sold 4,004,330 shares at average price of $1.27 from April 1 to June 5, 2026
- Net proceeds of $4.9 million after fees and expenses
- Compliance plan submitted May 25, 2026
- Extension granted to October 7, 2026 to regain compliance
- Company believes stockholders equity now exceeds $2.5 million as of filing date June 12, 2026
Why it matters
BioCardia cured a Nasdaq stockholders equity deficiency through equity capital raise, but remains on a compliance extension through October 7, 2026; failure to maintain the $2.5 million threshold at the next periodic report could trigger delisting proceedings.
Share
Get the next chapter in your inbox — a Sentinel watches this company and briefs the next material filing the moment it lands.
Derived from 8-K filed 2026-06-12. Not investment advice. View the source filing on SEC.gov →